Immunomedics Inc. (IMMU)

22.78
NASDAQ : Health Technology
Prev Close 22.58
Day Low/High 22.35 / 22.92
52 Wk Low/High 7.17 / 23.18
Avg Volume 2.01M
Exchange NASDAQ
Shares Outstanding 167.35M
Market Cap 3.78B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOCC, FET, IMMU, INVA, KMDA, SPH Downgrades: COR, EARN, EML, ENS, MSON, MYL, NCR, OFC, PBH, PCYO, THR, UBA, UBNT, UFS, WHG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.

Interesting IMMU Put And Call Options For December 15th

Interesting IMMU Put And Call Options For December 15th

Investors in Immunomedics, Inc. saw new options become available this week, for the December 15th expiration.

Short Interest Declines 14% For IMMU

Short Interest Declines 14% For IMMU

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 4,840,764 share decrease in total short interest for Immunomedics, Inc. , to 29,775,931, a decrease of 13.98% since 09/15/2017.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology

Immunomedics Announces Results Of Special Stockholder Meeting

Immunomedics Announces Results Of Special Stockholder Meeting

Obtains stockholder approval to increase authorized capital stock

Commit To Purchase Immunomedics At $4, Earn 12.5% Using Options

Investors eyeing a purchase of Immunomedics, Inc. shares, but tentative about paying the going market price of $7.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.

TheStreet Quant Rating: C- (Hold)